WeDoctor has raised $1.0B in total across 3 funding rounds.
WeDoctor's investors include 5Y Capital, Qiming Venture Partners.
WeDoctor (formally We Doctor Holdings Limited) is a Hangzhou-based technology company that operates one of China's largest digital healthcare platforms, connecting patients with hospitals, doctors, pharmacies, insurance, and financial services through mobile apps and cloud tools.[1][2] Founded in 2010 as an online appointment booking service (Guahao.com), it has evolved into a comprehensive "internet hospital" offering online consultations, AI-driven diagnostics, electronic prescriptions, insurance products, and hardware like the WeDoctor Tong home device, serving over 240 million registered users and 27 million monthly active users across 2,700+ hospitals.[1][2][3] It addresses core healthcare pain points—time, distance, and cost—by enabling 30-second consultations, real-time data analysis for precise predictions (e.g., heart attacks), and one-stop services from virtual visits to medication delivery, with strong growth evidenced by 18 million consultations in 2020 (up 38% YoY) and a $7 billion IPO filing valuation in 2021 backed by Tencent and others.[1][3][6]
WeDoctor was founded in 2010 by Jerry Liao Jieyuan, an artificial intelligence expert, starting as Guahao.com—a simple online platform (initially launched around 2004 per some records) to help patients book doctor appointments amid China's overburdened healthcare system, where long waits and scalpers were rampant.[2][3][4][5] Liao's vision stemmed from transforming fragmented healthcare; by 2015, after raising nearly $400 million from investors like Tencent, Goldman Sachs, and Hillhouse Capital, it rebranded to WeDoctor and expanded beyond bookings to full-service telemedicine, opening its first physical hospital in Zhejiang.[1][3][6] Early traction came from cloud-based connectivity linking patients and providers, quickly scaling to millions of users; pivotal moments included AI integrations for diagnostics, the $600 WeDoctor Tong device launch, and international moves like acquiring Australia's Genea for fertility tech.[1][3][5]
WeDoctor stands out in China's digital health space through integrated tech and ecosystem depth:
WeDoctor rides China's digital health revolution, fueled by rising inequalities, urban-rural healthcare gaps, an aging population, and post-COVID demand for contactless care, where traditional systems strain under patient volumes (e.g., hours-long waits).[1][7][9] Timing aligns with government pushes for "internet hospitals" and AI in medicine, amplified by Tencent's backing and the 2020-2021 telemedicine boom (WeDoctor's consultations surged 38% YoY).[6][8] Market forces like big data proliferation and insurer/pharma integrations favor it, positioning WeDoctor as a bridge between fragmented providers and consumers—much like Amazon in e-commerce—while influencing the ecosystem via tools exported to 50,000+ global users during pandemics and acquisitions abroad.[1][5][8] It competes with Ping An Good Doctor but differentiates through hospital depth over insurance-led models.[6]
WeDoctor's trajectory points to global expansion and AI dominance, building on its $7B valuation, Investcorp acquisition (2020), and hospital infrastructure to capture telemedicine's next wave amid China's healthcare digitization.[2][6] Trends like wearable integration, predictive AI, and personalized insurance will propel it, potentially evolving into a cross-border "health super-app" via stakes like Genea and tools for international crises.[1][8] As digital health matures, its data flywheel could amplify influence, pressuring incumbents and enabling precise, accessible care worldwide—proving that solving China's healthcare bottlenecks scales the "Amazon of Healthcare" model globally.[5][9]
WeDoctor has raised $1.0B across 3 funding rounds. Most recently, it raised $500.0M Venture Round in May 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2018 | $500.0M Venture Round | 5Y Capital | |
| Sep 1, 2015 | $390.0M Series C | 5Y Capital | |
| Oct 1, 2014 | $110.0M Series B | 5Y Capital, Qiming Venture Partners |
